Geny Piro - Concepedia

Author

Geny Piro

University of Verona ORCID

Also Known As

G PIRO, G Piro, G. Piro, GENY PIRO, Geny Piro, Piro, Geny

172

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

University of Verona Agostino Gemelli University Polyclinic Istituti di Ricovero e Cura a Carattere Scientifico Università Cattolica del Sacro Cuore Azienda Ospedaliera Universitaria Integrata Verona

About

Geny Piro is an author at University of Verona specializing in medicine, cancer research, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	159
2	Pathology	4	4	107
3	Cell Biology	3	3	87
4	Immunology	3	3	121
5	Health Sciences	1	1	13

Geny Piro

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 Rosalinda Trovato, Alessandra Fiore, S Sartori, Journal for ImmunoTherapy of Cancer	2019	183
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT Francesca Bruzzese, Alessandra Leone, Monia Rocco, Journal of Cellular Physiology	2010	140
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy Anna Tamburrino, Geny Piro, Carmine Carbone, Frontiers in Pharmacology	2013	109
An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients Geny Piro, Carmine Carbone, Ivana Cataldo, Clinical Cancer Research	2016	84
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer Carmine Carbone, Geny Piro, Antonio Agostini, Journal for ImmunoTherapy of Cancer	2021	70
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis Carmine Carbone, Geny Piro, Matteo Fassan, Oncotarget ImmunologyPathologyPancreatic Ductal CarcinogenesisCancer BiologyTumor Biology	2014	62
Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells Maria Rita Milone, Biagio Pucci, Francesca Bruzzese, Cell Death and Disease	2013	61
TAK -ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy Raffaela Santoro, Carmine Carbone, Geny Piro, Drug Resistance Updates	2017	57
Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer Raffaela Santoro, Marco Zanotto, Francesca Simionato, Molecular Cancer Therapeutics	2019	57
A circulating T<sub>H</sub>2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma Geny Piro, Francesca Simionato, Carmine Carbone, OncoImmunology	2017	53

Page 1